Analysis of public clinical and business development data in life sciences.
Bispecifics are protein therapeutics that engage T-cells with a target; recently showing tremendous amount of growth in the clinic and research:
Source: BioCentury
With Regeneron being the largest leader in the field:
Source: Regeneron
Where the average bispecific deal value increasing over time and a share increase in the number of partnerships in 2014/2015 when cell therapies were getting approved and bispecifics were seen as a viable/lower cost alternative:
With the deals focused on oncology:
And development and licensing agreements:
Focused on discovery and preclinical work:
With deals having no geographic preference:
Thank you.